4 recruiting, 3 unknown, 2 completed, 2 not yet recruiting. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Not yet recruiting 2, Unknown 2, Terminated 1 |
| Phase 1 | 5 | Completed 2, Unknown 2, Terminated 1 |
Follow SHR2554: new trials by email Literature Review of SHR2554 trials Research Report on SHR2554
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma Mosunetuzumab, Zeprumetostat - Follicular Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 80 | 2026-04-10 | 2026-06-09 |
| SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer SHR2554, HRS-8080 - Advanced Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 30 | 2025-10-14 | 2026-10-15 |
| PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer SHR1701, SHR2554, CAPOX - Advanced Gastric Cancer, SHR1701 | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 78 | 2025-06-15 | 2026-09-01 |
| SHR-1701 Combined with SHR2554 and BP102 for MCRC SHR-1701, BP102, SHR2554 - Colorectal Cancer Metastatic | Phase 2 | Not yet recruiting | Fudan University | 20 | 2024-12-01 | 2024-11-07 |
| A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma SHR2554 - Follicular Lymphoma | Phase 2 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 105 | 2024-04-01 | 2024-04-16 |
| Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects SHR2554 - Malignant Tumor | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2022-11-15 | 2022-12-19 |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Azacitidine Injection, Dasatinib, Linperlisib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 116 | 2022-09-30 | 2022-11-09 |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer SHR7390, Famitinib, SHR3162 - Breast Cancer, Metastatic Cancer | Phase 2 | Unknown | Fudan University | 319 | 2020-05-01 | 2022-07-26 |
| A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects SHR2554 - Healthy Adult Subjects | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2019-08-06 | 2020-04-06 |
| A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC SHR3680, SHR2554 - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 9 | 2018-11-20 | 2021-02-05 |
| A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms SHR2554 - Relapsed or Refractory Mature Lymphoid Neoplasms | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 272 | 2018-08-14 | 2024-10-01 |
Lymphoma, Follicular (2) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1) · Urinary Bladder Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (5) · Fudan University (2) · Henan Cancer Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Ruijin Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The First Affiliated Hospital of Zhengzhou University (1)
China (12)
Dingwei Ye, M.D. (1) · Min Yan, Chief physician (1) · Weili Zhao (1) · Zhi-Ming Shao (1)